)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Orchestra BioMed
Orchestra BioMed (OBIO) investor relations material
Orchestra BioMed Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary10 Aug, 2026
Executive summary
Focused on advancing AVIM Therapy and Virtue SAB, both in pivotal trials targeting large market opportunities, with BACKBEAT trial on track for 284 evaluable patients by end of Q3 2026 and primary data expected in Q2 2027.
Virtue pivotal trial is progressing with additional site activations and patient enrollments.
$110 million cash balance at quarter-end, bolstered by $35 million in strategic capital from Medtronic and Ligand, provides runway into Q4 2027.
Added to the Russell 3000 and Russell 2000 indexes in June 2026, increasing visibility among institutional investors.
R&D Day scheduled for November 12, 2026, to review AVIM Therapy and Virtue SAB programs.
Financial highlights
Cash and marketable securities totaled $110.0 million as of June 30, 2026.
Total revenue for the six months ended June 30, 2026 was $198,000, down 88% year-over-year due to the termination of a major partnership.
Research and development expenses rose 20% year-over-year to $16.6 million in Q2 2026 and 18% year-over-year to $32.4 million for the six months ended June 30, 2026, driven by clinical trial activity.
Selling, general and administrative expenses decreased 7% year-over-year to $5.8 million in Q2 2026 and 3% year-over-year to $12.2 million for the six months ended June 30, 2026.
Net cash used in operating activities was $41.5 million for the six months ended June 30, 2026, and $19.6 million in Q2 2026, mainly due to increased R&D and personnel costs.
Outlook and guidance
Cash and marketable securities are expected to fund operations into Q4 2027, supporting advancement of pivotal programs through key milestones.
Ongoing pivotal trials for AVIM Therapy and Virtue SAB are prioritized, with major clinical milestones expected in 2027.
BACKBEAT Trial expected to reach enrollment target by end of Q3 2026, with primary endpoint data presentation planned for Q2 2027.
Additional capital may be raised through equity, debt, or partnerships as needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Orchestra BioMed
- Strategic financing fuels pivotal AVIM trial and advances Virtue's sirolimus drug delivery innovation.OBIO
Piper Sandler 37th Annual Healthcare Conference - All proposals passed, directors re-elected, and annual compensation vote frequency set.OBIOAGM 2026
- Pivotal cardiovascular device trials progress with strong partners and funding, targeting 2028 launches.OBIOSidoti Small-Cap Virtual Investor Conference
- 2026 Employee Stock Purchase Plan approved, enabling employees to acquire up to 750,000 shares.OBIOProxy filing
- Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven value.OBIOJefferies Global Healthcare Conference 2026
- Pivotal cardiovascular therapies advance toward commercialization with strong partner support.OBIOCorporate presentation
- Net loss widened to $20.7M as R&D spending rose, with cash runway into Q4 2027 and new FDA designation.OBIOQ1 2026
- Board recommends approval of all annual meeting proposals, including compensation and governance.OBIOProxy filing
- Key votes include director elections, auditor ratification, and executive pay approval.OBIOProxy filing
Next Orchestra BioMed earnings date
Q3 202611 Nov, 2026
Orchestra BioMed
Next Orchestra BioMed earnings date
Q3 202611 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage